Cargando…
Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
BACKGROUND: Accurate outcome prediction in neuroblastoma, which is necessary to enable the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma patient stratification, this study aimed to identify prognostic tumor DNA methylation biomarkers. RESULTS: To identify gene...
Autores principales: | Decock, Anneleen, Ongenaert, Maté, Hoebeeck, Jasmien, De Preter, Katleen, Van Peer, Gert, Van Criekinge, Wim, Ladenstein, Ruth, Schulte, Johannes H, Noguera, Rosa, Stallings, Raymond L, Van Damme, An, Laureys, Geneviève, Vermeulen, Joëlle, Van Maerken, Tom, Speleman, Frank, Vandesompele, Jo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491423/ https://www.ncbi.nlm.nih.gov/pubmed/23034519 http://dx.doi.org/10.1186/gb-2012-13-10-r95 |
Ejemplares similares
-
DNA methylation profiling of primary neuroblastoma tumors using methyl-CpG-binding domain sequencing
por: Decock, Anneleen, et al.
Publicado: (2016) -
The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy
por: Van Roy, Nadine, et al.
Publicado: (2009) -
Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma
por: Decock, Anneleen, et al.
Publicado: (2015) -
No evidence for involvement of SDHD in neuroblastoma pathogenesis
por: De Preter, Katleen, et al.
Publicado: (2004) -
CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23
por: Michels, Evi, et al.
Publicado: (2008)